Harrow Health, Inc. (HROW)
$27.24-3.54%Close
SELLCRISIS · day 24
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.0B
- Beta
- 0.24
- P/E (TTM)
- -27.45
- Short % float
- 27.45%
- Days to cover
- 12.4
- SI change
- +3.7%
- 1W
- -11.04%
- 1M
- -19.50%
- vs SPY 1W
- -10.06%
- vs SPY 1M
- -21.37%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 50
- VALUE
- 4
- GROWTH
- 46
- GARP
- 78
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC-62.3%
REV YoY-
ROE-103.9%
EPS YoY-
ROA-8.9%
GROSS73
OP2
NET-14
[VALUATION]
P/E TTM-27.45
P/E FWD14.14
SECTOR PE20.48
INDUSTRY PE19.11
P/B66.94
P/FCF-
EV/EBITDA110.47
EV/EBIT-
PEG0.29
FCF YIELD-
RISK
INT COV-
D/E1978.58
ALTMAN Z-
CURR RATIO2.24
ND/EBITDA-
BETA0.24
Company news
FAQ
- What is LOPJLB’s current signal on HROW?
- LOPJLB’s latest quantitative signal on Harrow Health, Inc. (HROW) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is HROW in?
- Harrow Health, Inc. (HROW) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Harrow Health, Inc. (HROW) do?
- Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several p…